A Phase 3 interventional study of Recombinant human growth hormone (r-hGH) in Infant, Small for Gestational Age, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Italy. Open to participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This open, multicentric, randomized, controlled study is planned to evaluate the correlation between gene expression, spontaneous catch-up growth and therapeutic response to Saizen in SGA children.
This open, multicentric, randomized, controlled study was planned to identify genes activated by hGH in SGA children responders to treatment (making it possible in the near future to better identify SGA children likely to benefit from hGH treatment). Furthermore, the study would hopefully allow to verify which genes were responsible of spontaneous catch-up growth in children with diagnosis of SGA at birth but above the third percentile for height at the age of 24 months, and if these genes were the same activated by hGH during the treatment in participants responders. Sixty children born at term (i.e. after the 37th completed week of gestation) and with a diagnosis of SGA (defined as a length less than tenth percentile according to the Italian reference table published by Bertini and Fabris) were planned to be enrolled in the study. Forty participants (group A) were still less than third percentile for height (according to the Tanner reference table) at the age of 24 months, the remaining 20 (group B) being more than or equal to third percentile (thus showing a spontaneous catch-up growth). Group A was randomized to receive Saizen at the daily dose of 0.067 mg/kg (Group A1) or no treatment (Group A2) for two years. All participants were to undergo full clinical examination and blood chemistry at baseline visit and visit after 1,6,12,18 and 24 months for a period of two years. Gene expression analysis using the Clontech Atlas Human Array was performed in all participants at baseline and after one year in order to identify the possible correlation between catch-up growth (either spontaneous or drug-induced) and expression of some genes.
OBJECTIVES
Primary objective:
Secondary Objectives:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
Drug: Recombinant human growth hormone (r-hGH)
Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
Also known as: Saizen
Correlation Between Gene Expression Profiling and Catch-up Growth in Small for Gestational Age (SGA) Children
Gene expression profiling:analysis of ribonucleic acid (RNA) extracted from body tissue or fluids using Clontech Atlas Human Array to study level of activation of genes in tissue analyzed. Analysis was performed to identify possible correlation between catch-up growth (either spontaneous or drug-induced after Week 48) and therapeutic response to rhGH. Spontaneous catch up growth:shown by SGA participants having length more than third percentile at Week 96 without any treatment;drug induced growth was by SGA participants having length more than third percentile at Week 96 with drug treatment.
Time frame: Baseline and Week 48
Percentage of Untreated Participants Who Showed a Spontaneous Catch-up Growth
Spontaneous catch up growth was the growth shown by SGA participants having length more than third percentile at Week 96 without any study drug treatment.
Time frame: Baseline through Week 96
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.
Time frame: Baseline through Week 96
Participants were recruited in 12 study centers in Italy from 20 Feb 2004 to 10 Jul 2009.
| Milestone | Group A, Less Than Third Percentile (Saizen) | Group A2, Less Than Third Percentile (No Treatment) | Group B, More Than Third Percentile (No Treatment) |
|---|---|---|---|
| Started | 9 | 6 | 10 |
| Completed | 8 | 3 | 9 |
| Not completed | 1 | 3 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
Gene expression profiling:analysis of ribonucleic acid (RNA) extracted from body tissue or fluids using Clontech Atlas Human Array to study level of activation of genes in tissue analyzed. Analysis was performed to identify possible correlation between catch-up growth (either spontaneous or drug-induced after Week 48) and therapeutic response to rhGH. Spontaneous catch up growth:shown by SGA participants having length more than third percentile at Week 96 without any treatment;drug induced growth was by SGA participants having length more than third percentile at Week 96 with drug treatment.
No measurements were reported for this outcome.
Spontaneous catch up growth was the growth shown by SGA participants having length more than third percentile at Week 96 without any study drug treatment.
No measurements were reported for this outcome.
AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug , SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued from the study due to AE were also recorded.
| participants | Group A, Less Than Third Percentile (Saizen) | Group A2, Less Than Third Percentile (No Treatment) | Group B, More Than Third Percentile (No Treatment) |
|---|---|---|---|
| AEs | 6 | 4 | 9 |
| SAEs | 0 | 0 | 0 |
| Discontinuation due to AEs | 0 | 0 | 0 |
Collected over AEs were collected on an ongoing basis from day of written informed consent. All new AEs were recorded until the post-treatment safety, on Day 30 post-drug administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A, Less Than Third Percentile (Saizen) | — | 0/8 (0%) | 6/8 (75%) |
| Group A2, Less Than Third Percentile (No Treatment) | — | 0/4 (0%) | 4/4 (100%) |
| Group B, More Than Third Percentile (No Treatment) | — | 0/10 (0%) | 9/10 (90%) |
| Event | Group A, Less Than Third Percentile (Saizen) | Group A2, Less Than Third Percentile (No Treatment) | Group B, More Than Third Percentile (No Treatment) |
|---|---|---|---|
| PyrexiaGeneral disorders | 6/8 | 2/4 | 4/10 |
| PharyngitisInfections and infestations | 1/8 | 2/4 | 2/10 |
| VaricellaInfections and infestations | 0/8 | 2/4 | 2/10 |
| BronchitisInfections and infestations | 2/8 | 1/4 | 3/10 |
| InfluenzaInfections and infestations | 0/8 | 0/4 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/4 | 0/10 |
| GastroenteritisInfections and infestations | 0/8 | 1/4 | 0/10 |
| TonsillitisInfections and infestations | 0/8 | 1/4 | 1/10 |
| Blood alkaline phosphatase increasedInvestigations | 0/8 | 1/4 | 0/10 |
| Blood cholesterol increasedInvestigations | 0/8 | 1/4 | 0/10 |
| Age, Continuous(years) | Group A, Less Than Third Percentile (Saizen) | Group A2, Less Than Third Percentile (No Treatment) | Group B, More Than Third Percentile (No Treatment) | Total |
|---|---|---|---|---|
| Mean | 5.7 ± 1.2 | 5.0 ± 0.7 | 5.2 ± 0.4 | 5.3 ± 0.9 |
| Sex: Female, Male(Participants) | Group A, Less Than Third Percentile (Saizen) | Group A2, Less Than Third Percentile (No Treatment) | Group B, More Than Third Percentile (No Treatment) | Total |
|---|---|---|---|---|
| Female | 4 | 4 | 5 | 13 |
| Male | 5 | 2 | 5 | 12 |
The record gives a start of Feb 2004, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →